TanyaBDorffMD

Oncology • Duarte, CA

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Medicine Section Chief, Division of Genitouronary Cancers City of Hope

Join to view full profile

Dr. Dorff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dorff's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-218-8233

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2005 - 2006
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2004 - 2005
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2003 - 2004
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2000 - 2003
David Geffen School of Medicine at UCLAClass of 2000

Certifications & Licensure

CA State Medical License 2003 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013

Clinical Trials

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Short-Term Fasting: Impact on Toxicity Start of enrollment: 2009 Jul 09
Active, not recruiting
Not Applicable
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2012 Sep 01
Unknown status
Phase 2
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Start of enrollment: 2013 Jan 29
Active, not recruiting
Not Applicable
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer Start of enrollment: 2009 Jan 01
Completed
Not Applicable
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer Start of enrollment: 2016 Aug 02
Terminated
Phase 1
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2018 Nov 21
Active, not recruiting
Phase 2
A Study of Olaparib and Durvalumab in Prostate Cancer Start of enrollment: 2019 Mar 07
Terminated
Phase 2
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Aug 20
Active, not recruiting
Phase 1
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Start of enrollment: 2021 May 04
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
Alexander Chehrazi-Raffle, Ramya Muddasani, Nazli Dizman, JoAnn Hsu, Luis Meza
JCO Precision Oncology. 2023-04-01
37 citations
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S Lopez, Rachel H Ng
Journal for Immunotherapy of Cancer. 2022-06-01
1166 citations
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D'Amico, Brian J. Davis
Journal of the National Comprehensive Cancer Network. 2019-05-01

Lectures

Closing the Gap: Knowledge Gaps and Interpreting Current Data in the Era of Novel Imaging — Medical...
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
A randomized phase II clinical trial of a fasting-mimic diet prior to chemotherapy to evaluate the impact on toxicity and efficacy.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

CAR-T Immunotherapy for Prostate Cancer?September 16th, 2024
Overview of Efficacy and Safety Data of Combination Therapy with PARPi and NHAsMarch 27th, 2023
Treatment Options for Advanced HCC Patients Who Are Not Eligible for IO First LineMarch 14th, 2023
Join now to see all